Puma Biotechnology Lifts 2026 Profit Outlook To $20 Million-$22 Million, Vows More Cost Cuts If Needed

The cancer-drug maker raised its 2026 net income guidance even as new patient starts for Nerlynx fell and a China royalty cut hit.

Share
Puma Biotechnology Lifts 2026 Profit Outlook To $20 Million-$22 Million, Vows More Cost Cuts If Needed

Puma Biotechnology, which develops and sells cancer drugs, raised its 2026 net income guidance to $20 million to $22 million, from $17 million to $20 million, and CEO Alan Auerbach said on Thursday's third-quarter earnings call the company "will continue to reduce expenses if needed" to get there.

Demand softens, guidance firms

Auerbach said new prescriptions for the breast cancer drug Nerlynx were down about 13% from the second quarter and total prescriptions about 5%, though the transcript of that remark is garbled. Roger Storms, Puma's senior vice president of sales, said commercial new patient starts fell 13% from the prior quarter and 9% from a year earlier.

Storms said sales call activity dropped 8% year over year, which he blamed on a temporary rise in vacancies and time off territory that he said were expected to normalize shortly. Nerlynx ex-factory bottle sales were 2,818 in the quarter, versus 2,929 in the second quarter.

Net product revenue was $54.1 million, up from $53.6 million in the second quarter and $51.9 million a year earlier. Total revenue was $55.1 million. U.S. net sales were $50.6 million versus $53.6 million in the second quarter, after $3.6 million of supply revenue to international partners.

A China royalty cut and richer rebates

Chief Financial Officer Maximo Nougues said third-quarter royalty revenue was $0.9 million, down from $2.9 million in the second quarter. Puma booked a $2.1 million cumulative cut after October third-party data showed generic versions of Nerlynx hit a market-share threshold in China during 2025, which lowers the royalty rate going forward.

Full-year royalties are now seen at $18 million to $19 million, from $20 million to $23 million. Nougues trimmed net Nerlynx product revenue guidance to $205 million to $208 million from $205 million to $209 million. He raised the expected gross-to-net discount to 27.5% to 28%, mostly on higher Medicaid share.

GAAP net income was $6 million, or 11 cents a diluted share, versus $8.2 million in the second quarter. For the fourth quarter, Puma guides to net income of $10 million to $12 million.

Debt-free, with cash of $108.5 million

Puma made its final loan payment of $11.1 million in the second quarter and is now debt-free, Nougues said. It held about $108.5 million in cash and marketable securities on September 30, against $97.5 million at the end of 2025.

Auerbach called positive net income a fiscal responsibility to shareholders. SG&A expenses fell to $16.3 million from $17.5 million in the second quarter, while R&D was $18.3 million; management expects R&D to rise 28% to 30% this year on its clinical trials.

Puma holds rights to the experimental drug alisertib. The company plans to present updated breast cancer data at the San Antonio Breast Cancer Symposium in December and to engage regulators on a Phase 3 design in the first half of 2027.

Puma's market value was about $552 million as of the original report on Friday, and the December San Antonio presentation is the next scheduled data point for alisertib.

Sources

More on Puma Biotechnology

All Puma Biotechnology (PBYI) coverage →